818 related articles for article (PubMed ID: 25534420)
1. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
2. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
4. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study.
Kim SC; Schneeweiss S; Liu J; Karlson EW; Katz JN; Feldman S; Solomon DH
Arthritis Rheumatol; 2016 Sep; 68(9):2106-13. PubMed ID: 27015113
[TBL] [Abstract][Full Text] [Related]
5. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
7. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
8. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
9. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Desai RJ; Solomon DH; Schneeweiss S; Danaei G; Liao KP; Kim SC
Epidemiology; 2016 May; 27(3):414-22. PubMed ID: 26808597
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
11. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
12. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
J Rheumatol; 2017 May; 44(5):565-570. PubMed ID: 28250142
[TBL] [Abstract][Full Text] [Related]
13. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
15. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
Kim SC; Yelin E; Tonner C; Solomon DH
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1529-33. PubMed ID: 23463543
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
18. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
19. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
Solomon DH; Kremer JM; Fisher M; Curtis JR; Furer V; Harrold LR; Hochberg MC; Reed G; Tsao P; Greenberg JD
Semin Arthritis Rheum; 2014 Feb; 43(4):489-97. PubMed ID: 24012043
[TBL] [Abstract][Full Text] [Related]
20. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.
Desai RJ; Eddings W; Liao KP; Solomon DH; Kim SC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):457-66. PubMed ID: 25302481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
